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cause of ketosis-prone diabetes, including other 
coronaviruses that bind to ACE2 receptors.5 
Greater incidences of fasting glycemia and acute-
onset diabetes have been reported among pa-
tients with SARS coronavirus 1 pneumonia than 
among those with non-SARS pneumonia.5
In the aggregate, these observations provide 
support for the hypothesis of a potential diabeto-
genic effect of Covid-19, beyond the well-recog-
nized stress response associated with severe ill-
ness. However, whether the alterations of glucose 
metabolism that occur with a sudden onset in 
severe Covid-19 persist or remit when the infec-
tion resolves is unclear. How frequent is the 
phenomenon of new-onset diabetes, and is it 
classic type 1 or type 2 diabetes or a new type of 
diabetes? Do these patients remain at higher risk 
for diabetes or diabetic ketoacidosis? In patients 
with preexisting diabetes, does Covid-19 change 
the underlying pathophysiology and the natural 
history of the disease? Answering these ques-
tions in order to inform the immediate clinical 
care, follow-up, and monitoring of affected pa-
tients is a priority.
To address these issues, an international group 
of leading diabetes researchers participating in 
the CoviDIAB Project have established a global 
registry of patients with Covid-19–related diabe-
tes (covidiab . e - dendrite . com). The goal of the 
registry is to establish the extent and phenotype 
of new-onset diabetes that is defined by hyper-
glycemia, confirmed Covid-19, a negative history 
of diabetes, and a history of a normal glycated 
hemoglobin level. The registry, which will be 
expanded to include patients with preexisting 
diabetes who present with severe acute meta-
bolic disturbance, may also be used to investi-
gate the epidemiologic features and pathogene-
sis of Covid-19–related diabetes and to gain clues 
regarding appropriate care for patients during 
and after the course of Covid-19. Given the very 
short history of human infection with SARS-
CoV-2, an understanding of how Covid-19–related 
diabetes develops, the natural history of this 
disease, and appropriate management will be 
helpful. The study of Covid-19–related diabetes 
may also uncover novel mechanisms of disease.
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Randomized Trial of Lactin-V to Prevent Recurrence  
of Bacterial Vaginosis
To the Editor: In their trial of Lactobacillus crispa-
tus CTV-05 (Lactin-V), Cohen et al. (May 14 issue) 
offer hope for the prevention of bacterial vagino-
sis.1 The protective effect of the treatment was 
modest, similar to twice-weekly metronidazole,2,3 
but the L. crispatus CTV-05 strain could still be 
detected in 48% of participants 13 weeks after 
the last administration. This finding is encour-
aging, but in order to interpret the effects of 
Lactin-V properly, we would like to see additional 
data. First, previous trials of lactobacilli-contain-
ing vaginal probiotics have shown large variabil-
ity in treatment responses among women, as well 
as fluctuations in response in individual women, 
over time.4 Cohen et al. report a cumulative inci-
dence according to treatment group, thereby over-
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looking these variabilities. Second, sequencing 
or other data on the composition of the molecu-
lar vaginal microbiome — preferably quantified 
— are essential for interpretation.3,4 Unlike micros-
copy, molecular methods can differentiate be-
tween autologous and biotherapeutic lactobacilli, 
which enables microbiome data obtained at all 
trial visits, including those that occurred during 
treatment with Lactin-V, to be used in longitudi-
nal modeling. Molecular methods also enable 
estimation of the relative abundance of lactoba-
cilli and bacterial vaginosis–associated anaerobes 
over time. Clinical symptoms are important out-
comes in their own right, but microscopy-based 
Amsel criteria and Nugent scores should be ac-
companied by molecular data.
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To the Editor: Cohen et al. report on a potential 
treatment for recurrent bacterial vaginosis. Wom-
en arrived at the trial screening clinic. (I could 
not find a description of the way in which they 
were recruited.) Bacterial vaginosis was diag-
nosed on the basis of the Amsel criteria and the 
Gram’s staining–based Nugent score; the pres-
ence of symptoms was not required for diagno-
sis. I could not find how many participants had 
symptoms at entry nor whether treatment affect-
ed the symptoms in the participants who had 
them. Some symptoms of bacterial vaginosis were 
reported as adverse events in some participants.
The U.S. Preventive Services Task Force rec-
ommends against screening for bacterial vagino-
sis in pregnant women who are not at risk for 
preterm delivery; for pregnant women who have 
such a risk, no recommendation is made, be-
cause current evidence is insufficient.1 I could 
find no recommendation for or against screen-
ing in nonpregnant women.
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The authors reply: Van de Wijgert and Verwijs 
raise questions about individual and temporal 
variability in responses to Lactin-V treatment, as 
well as about the use of molecular methods. A 
preliminary quantitative polymerase-chain-reac-
tion assay distinguished the L. crispatus CTV-05 
strain we evaluated from endogenous L. crispatus. 
To assess sustained colonization at relevant con-
centrations and fluctuations over time in relation 
to the presence of competing lactobacillus strains 
(such as L. iners) and other bacteria, we are cur-
rently performing additional analyses on vaginal 
samples obtained at all trial visits using molecu-
lar methods. The aim of DNA and RNA sequenc-
ing of the vaginal microbiome is to identify as-
sociations of clinical, microbial, host genetic, 
and ecological factors with loss or retention of 
L. crispatus CTV-05 and with recurrence of bacte-
rial vaginosis. We agree that molecular methods 
should routinely be included in future clinical 
trials of treatment and prevention of bacterial 
vaginosis to allow for interpretation of findings 
in greater depth and to advance our understand-
ing of the female genital microbiome.
In response to Finucane: Recruitment strate-
gies varied across the trial sites. Many women 
learned of the trial through social media, Google 
searches, and flyers in local clinics and in loca-
tions frequented by women, and they referred 
themselves after recognizing bacterial vaginosis 
as being relevant to their health. Other women 
were contacted through mass mailings sent to 
previous patients who had received a diagnosis 
of bacterial vaginosis or were referred by clini-
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cians who had diagnosed cases of bacterial 
vaginosis.
The determination of whether a woman has 
asymptomatic or symptomatic bacterial vagino-
sis drives decisions in clinical practice; often, 
only women who report symptoms will receive 
treatment. Although only half of women with 
bacterial vaginosis have symptoms,1 whether a 
woman has symptoms does not seem to affect 
the association of bacterial vaginosis with sexu-
ally transmitted infections, including human im-
munodeficiency virus infection.2 As has been the 
case in other recent clinical trials,3-5 we enrolled 
women with or without patient-reported symp-
toms of bacterial vaginosis at screening as long 
as bacterial vaginosis was subsequently diag-
nosed on the basis of the Amsel criteria and the 
Nugent score.
Although women were not specifically queried 
about symptoms of bacterial vaginosis at screen-
ing, one can assume that most of the women 
scheduled a screening visit because of current or 
recent symptoms of bacterial vaginosis such as 
abnormal vaginal discharge and odor. At screen-
ing, 165 of the 228 participants (72.4%) had 
abnormal vaginal discharge, as recorded by the 
trial investigators.
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Pulmonary Disease Related to E-Cigarette Use
To the Editor: Layden et al. (March 5 issue)1 
reported the results of a public health investiga-
tion of e-cigarette, or vaping, product use–asso-
ciated lung injury (EVALI). Surveillance for can-
nabis use with precise analytical data is 
paramount in the evolving EVALI epidemic. More 
than 60% of cannabis users report vaping,2 and 
89% of patients with EVALI in the study by 
Layden et al. reported having used tetrahydro-
cannabinol (THC) vaping products. It is unclear 
whether any clinical laboratory or drug testing 
corroborating this information was ever obtained 
for this study. Our inpatient toxicology service 
has found that all six patients whose conditions 
have met the Centers for Disease Control and 
Prevention (CDC) definition of EVALI have pre-
sented with urinary 11-nor-9-carboxy-Δ9-THC 
(THC-COOH) levels higher than 200 ng per milli-
liter; in the majority of patients, the levels were 
higher than the available laboratory assay limit 
(500 ng per milliliter). Two thirds of the patients 
had evidence of hyperemesis cannabinoid syn-
drome, and one had signs of cannabis withdrawal 
during his hospital stay. Existing studies3 of uri-
nary concentrations of THC-COOH after canna-
bis vaping have shown a mean maximum con-
centration of approximately 40 ng per milliliter 
— well below the levels we observed. Given this 
finding and the fact that cannabis levels may in-
dicate vitamin E acetate exposure,4,5 we suggest 
that further surveillance and clinical evaluation 
protocols target precise measurements of canna-
bis and metabolite levels.
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